BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer - Concepedia

Concepedia

Publication | Closed Access

BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer

41

Citations

29

References

2006

Year

Seiji Nagashima, Hiroshi Soda, Mikio Oka, Takeshi Kitazaki, Ken Shiozawa, Yoichi Nakamura, Masaaki Takemura, Hikaru Yabuuchi, Minoru Fukuda, Kazuhiro Tsukamoto,

Cancer Chemotherapy and Pharmacology

Bcrp/abcg2 LevelsMedicinePathologyCancer GenomicsBronchial NeoplasmReversal EffectsCancer TreatmentCancer GeneticsOncologyRadiation OncologyLung CancerTumor Biology

References

	Year	Citations

Page 1

Page 1